---
title: "Sonoma Pharmaceuticals Prices $1.35 Unit Offering, Nets ~$3.5M Under Underwriting With Dawson James"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284836615.md"
description: "Sonoma Pharmaceuticals has completed a public offering of 2,962,962 units at $1.35 each, netting approximately $3.5 million. The offering, underwritten by Dawson James Securities, included 1,650,716 common shares, 1,312,247 pre-funded warrants, and 3,407,404 common warrants. The offering closed on April 27-28, 2026, with a fully exercised 45-day over-allotment option. Sonoma also appointed Computershare as the warrant agent for the offering's warrants, effective April 28, 2026."
datetime: "2026-04-30T21:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284836615.md)
  - [en](https://longbridge.com/en/news/284836615.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284836615.md)
---

# Sonoma Pharmaceuticals Prices $1.35 Unit Offering, Nets ~$3.5M Under Underwriting With Dawson James

Sonoma Pharmaceuticals entered into an underwriting agreement with Dawson James Securities to complete a public offering of 2,962,962 units at $1.35 per unit. The underwriter's 45-day over-allotment option was fully exercised, and the offering closed April 27–28, 2026. Sonoma sold 1,650,716 common shares, 1,312,247 pre-funded warrants, and 3,407,404 common warrants, yielding approximately $3.5 million in net proceeds. The company also signed warrant agency agreements with Computershare and Computershare Trust Company to administer the offering's pre-funded and common warrants.

**Agreement 1: Sonoma Pharmaceuticals Prices $1.35 Unit Offering, Nets ~$3.5M Under Underwriting With Dawson James**

-   **Agreement type**: Underwriting agreement for public equity offering
-   **Counterparty**: Dawson James Securities
-   **Signed / Effective**: Apr 24 2026 / Apr 24 2026
-   **Duration / Termination**: Offering period; 45-day over-allotment; 90-day lock-up
-   **Reason**: Raise equity capital and enhance liquidity

**Agreement 2: Sonoma Pharmaceuticals Appoints Computershare as Warrant Agent for Offering Warrants**

-   **Agreement type**: Warrant agency agreements for pre-funded and common warrants
-   **Counterparty**: Computershare; Computershare Trust Company
-   **Signed / Effective**: Apr 28 2026 / Apr 28 2026
-   **Duration / Termination**: Through warrant expirations (up to 5 years)
-   **Reason**: Administer warrant issuance and exercises from the offering

Original SEC Filing: Sonoma Pharmaceuticals, Inc. \[ SNOA \] - 8-K - Apr. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SNOA.US](https://longbridge.com/en/quote/SNOA.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [CPU.AU](https://longbridge.com/en/quote/CPU.AU.md)

## Related News & Research

- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)